Expression of angiotensin type II receptor downregulates Cdk4 synthesis and inhibits cell-cycle progression

Bruno Gingras1, Geneviève Rodier, Edith Giasson

  • 1Institut de recherches cliniques de Montréal and Department of Pharmacology, Université de Montréal, 110 Pine Avenue West, Montreal, Quebec, Canada H2W 1R7.

Oncogene
|May 6, 2003
PubMed

Insights

The angiotensin II type II (AT(2)) receptor inhibits fibroblast proliferation by blocking cell cycle progression. This receptor

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Physiology

Background:

  • The angiotensin II type II (AT(2)) receptor is implicated in negatively regulating cell proliferation during tissue remodeling.
  • Mechanisms underlying AT(2) receptor's antiproliferative effects are not fully understood.

Purpose of the Study:

  • To elucidate the mechanisms by which AT(2) receptor expression inhibits cell proliferation.
  • To investigate the role of AT(2) receptor in cell cycle regulation.

Main Methods:

  • Studied AT(2) receptor expression in rat fibroblasts.
  • Assessed cell proliferation, cell cycle progression (G1 phase), and apoptosis.
  • Analyzed expression and activity of cyclins (E, Cdk4) and cyclin-dependent kinases (Cdk2).

Main Results:

  • AT(2) receptor expression inhibited fibroblast proliferation in a ligand-independent manner, dependent on receptor density.
  • AT(2) receptor negatively regulated G1 phase progression without affecting apoptosis.
  • Inhibition was linked to downregulated cyclin E, reduced cyclin E-Cdk2 complex formation, attenuated Cdk2 activation, and decreased Cdk4 induction.

Conclusions:

  • AT(2) receptor exerts growth-inhibitory effects by spontaneously inhibiting the cell cycle machinery.
  • The antiproliferative action involves downregulation of key cell cycle regulators like cyclin E and Cdk4.

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...